Obesity and cancer: mechanistic insights from transdisciplinary studies

Emma H Allott^{1,2} and Stephen D Hursting^{2,3}

¹Department of Epidemiology, CB 7435, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, North Carolina 27599, USA

²Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, North Carolina 27599, USA

³Department of Nutrition, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, North Carolina 27599, USA

Correspondence
should be addressed
to E H Allott

Email
allott@email.unc.edu

Abstract

Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer. Herein, we summarize epidemiologic and preclinical evidence for an association between obesity and increased risk of breast and prostate cancer incidence and mortality. Moreover, we describe data from observational studies of weight change in humans and from calorie-restriction studies in mouse models that support a potential role for weight loss in counteracting tumor-promoting properties of obesity in breast and prostate cancers. Given that weight loss is challenging to achieve and maintain, we also consider evidence linking treatments for obesity-associated co-morbidities, including metformin, statins and non-steroidal anti-inflammatory drugs, with reduced breast and prostate cancer incidence and mortality. Finally, we highlight several challenges that should be considered when conducting epidemiologic and preclinical research in the area of obesity and cancer, including the measurement of obesity in population-based studies, the timing of obesity and weight change in relation to tumor latency and cancer diagnosis, and the heterogeneous nature of obesity and its associated co-morbidities. Given that obesity is a complex trait, comprised of behavioral, epidemiologic and molecular/metabolic factors, we argue that a transdisciplinary approach is the key to understanding the mechanisms linking obesity and cancer. As such, this review highlights the critical need to integrate evidence from both epidemiologic and preclinical studies to gain insight into both biologic and non-biologic mechanisms contributing to the obesity-cancer link.

Key Words

- ▶ aspirin
- ▶ breast cancer
- ▶ cholesterol
- ▶ epidemiology
- ▶ insulin
- ▶ prostate cancer
- ▶ mechanisms
- ▶ metformin
- ▶ mouse models
- ▶ NSAIDs
- ▶ obesity
- ▶ screening
- ▶ statins
- ▶ transdisciplinary
- ▶ weight loss

Endocrine-Related Cancer
(2015) **22**, R365–R386

Introduction

Cancer is predicted to overtake heart disease as the leading cause of death across all age groups in the U.S. by 2030, translating to a 45% increase in the number of cancer diagnoses in the next 15 years (American Society of Clinical Oncology 2014). Global obesity prevalence has been increasing by approximately half a BMI unit per

decade over the past three decades, resulting in over 600 million adults worldwide with a BMI of 30 kg/m² or greater (Finucane *et al.* 2011, Stevens *et al.* 2012). With more than one in three U.S. adults classified as obese, the prevalence of obesity in the country is currently the highest in the Western world (Finucane *et al.* 2011, Ogden *et al.* 2014).

Obesity is associated with increased risk of a variety of different cancer types (World Cancer Research Fund 2007). Of these obesity-associated cancer types, almost 13% of incident cases worldwide, and ~20% of incident cases in Europe and North America, are attributable to obesity (Arnold *et al.* 2014). Furthermore, it is estimated that one quarter of these cases could have been avoided had the worldwide obesity prevalence not approximately doubled since 1980 (Arnold *et al.* 2014). Excess weight and obesity also drive cancer progression, and have been estimated to account for 14% of all cancer deaths in men and 20% in women in the United States (Calle *et al.* 2003), while ~6% of cancer deaths around the same time period in Europe were attributable to obesity (Banegas *et al.* 2003).

Cancers of the breast and prostate are among the most commonly diagnosed and among the leading causes of cancer deaths in women and men, respectively, both in the U.S. and worldwide (Jemal *et al.* 2011, Siegel *et al.* 2015). Therefore, understanding mechanisms linking obesity and risk of these common tumor types will be important for cancer prevention efforts worldwide. In addition, of over 11 million U.S. individuals living with cancer, survivors of breast cancer constitute the largest group (22%), followed by survivors of prostate cancer (19%) (Centers for Disease Control & Prevention 2011). Therefore, understanding mechanisms linking obesity and cancer progression in these common tumor types has great importance for a large proportion of cancer survivors, and will likely also benefit survivors of other obesity-associated cancer types. Molecular mechanisms linking obesity and cancer have been reviewed in depth elsewhere (Allott *et al.* 2013a, Ford *et al.* 2013a, Lashinger *et al.* 2014a). As such, this review adopts a transdisciplinary approach, summarizing findings from both epidemiologic and preclinical studies (Fig. 1), in addition to examining evidence for the modifiable nature of obesity and related co-morbidities through weight loss and pharmacologic interventions in both humans and mouse models. Finally, we consider how a transdisciplinary approach can minimize the weaknesses and maximize the strengths of each discipline, enabling a deeper understanding of mechanisms linking obesity and cancer.

Transdisciplinary insights into associations between obesity and cancer

Obesity and breast cancer

The association between obesity and breast cancer risk is complex, varying by menopausal status and by breast

Figure 1

Using a transdisciplinary approach to study mechanisms linking obesity and cancer.

cancer subtype. Obesity is associated with reduced breast cancer incidence in premenopausal women (World Cancer Research Fund 2007), but increased breast cancer incidence in postmenopausal women (World Cancer Research Fund 2007, Munsell *et al.* 2014), although the association with postmenopausal breast cancer is attenuated in women using hormone replacement therapy (Munsell *et al.* 2014). While these contrasting associations by menopausal status are consistently reported, differences in these associations by hormone receptor status are less well understood. Within postmenopausal breast cancers, there is a suggestion that the association with obesity is strongest among hormone receptor-positive cases (Althuis *et al.* 2004, Rosenberg *et al.* 2006, Suzuki *et al.* 2009, Canchola *et al.* 2012), although other studies did not find differences in these associations by breast cancer subtype (Millikan *et al.* 2008, Phipps *et al.* 2008, Yang *et al.* 2011). Several studies have reported that, although obesity is a protective factor for total premenopausal breast cancer, it is associated with increased risk of triple negative and basal-like disease in premenopausal women (Millikan *et al.* 2008, Gaudet *et al.* 2011, Yang *et al.* 2011). Interestingly, some evidence suggests that obesity may be a risk factor for basal-like breast cancer regardless of menopausal status (Millikan *et al.* 2008), suggesting a role for non-hormonal mechanisms in basal-like breast cancer pathogenesis.

While the association between obesity and breast cancer risk differs by menopausal status, obesity is associated with increased risk of breast cancer recurrence and mortality in both pre and postmenopausal women (Niraula *et al.* 2012, Chan *et al.* 2014). While several studies have suggested that this association may be stronger among women with hormone receptor-positive tumors (Sparano *et al.* 2012, Jiralerspong *et al.* 2013, Azrad & Demark-Wahnefried 2014, Tait *et al.* 2014), others reported no difference in the association between obesity and breast cancer-specific mortality by subtype (Phipps *et al.* 2008, Niraula *et al.* 2012). However, partial availability of subtype data and lower numbers of patients with rarer breast cancer subtypes is a limitation for many studies (Althuis *et al.* 2004). Given the evidence for etiologic heterogeneity of breast cancer, understanding the obesity-breast cancer link in humans requires large, well-annotated studies with sufficient power to conduct stratified analysis both by menopausal status and subtype.

The recognition of breast cancer as a heterogeneous disease has led to the characterization of mouse models that reflect human breast cancer subtypes (Herschkowitz *et al.* 2007). One particular challenge of preclinical models of breast cancer is that the estrogen receptor (ER) is weakly expressed in most mouse mammary tumors, particularly in genetically-engineered mice, and thus murine models of hormone receptor-positive breast cancer may not be fully representative of human luminal breast cancer (Herschkowitz *et al.* 2007, Borowsky 2011). Nonetheless, diet-induced obesity has been demonstrated to drive tumor growth in a variety of mouse models with both luminal (Pape-Ansorge *et al.* 2002, Ford *et al.* 2013b) and basal-like tumor characteristics (Dogan *et al.* 2007, Hakkak *et al.* 2007, Dunlap *et al.* 2012, Giles *et al.* 2012, Nogueira *et al.* 2012, Sundaram *et al.* 2013), lending support to epidemiologic observations. In contrast, there is little preclinical support for links between obesity and luminal B or HER-2 breast cancer subtypes (Cleary *et al.* 2004, Ford *et al.* 2013b), although the degree to which these models are representative of these human subtypes is unclear. Finally, one study showed that diet-induced obesity enhanced the growth of luminal-like tumors in ovariectomized mice but not in mice with intact ovaries (Nunez *et al.* 2008), suggesting that the relationship between obesity and postmenopausal luminal breast cancer should be tested in ovariectomized mice in order to model the human postmenopausal environment. However, given epidemiologic evidence supporting an association between obesity and basal-like breast cancer regardless of menopausal status, the relevance of ovariectomy to

study the impact of diet-induced obesity on basal-like breast cancer in mouse models is less clear.

Obesity and prostate cancer

Although individual studies are conflicted regarding the association between obesity and prostate cancer risk, a number of large meta-analyses have reported that obesity is associated with a modestly elevated total prostate cancer incidence (Bergstrom *et al.* 2001, MacInnis & English 2006, Renehan *et al.* 2008, Hu *et al.* 2014). One meta-analysis demonstrated that findings from the individual contributing studies differed by geographic region (Renehan *et al.* 2008), thereby offering insight into these somewhat conflicted results. Prostate-specific antigen (PSA) levels are reduced in obese men via hemodilution (Banez *et al.* 2007), thereby lowering the likelihood of a PSA-driven biopsy and giving rise to an obesity-associated detection bias. This bias becomes apparent when comparing the results of U.S. studies where PSA screening is widespread, with the results of European studies where PSA screening is less common (Renehan *et al.* 2008). In the U.S., where prostate biopsies are largely driven by PSA screening, obese men have a reduced chance of undergoing biopsy compared to normal-weight men, leading to the detection of fewer cancers in obese individuals and biasing the association between obesity and prostate cancer towards the null. In countries with lower PSA screening rates, such as Europe and Australia, this detection bias is reduced and the meta-analysis of studies from these regions demonstrates a positive association between obesity and prostate cancer risk (Renehan *et al.* 2008). These data highlight the importance of considering how the association between obesity and prostate cancer risk is impacted by the mode of cancer detection, particularly in the context of changing PSA screening recommendations in the U.S. (Moyer and U.S. Preventative Services Task Force 2012).

While the association between obesity and total prostate cancer is complicated by obesity-associated detection bias, there is consistent and convincing evidence for an association between obesity and elevated risk of aggressive prostate cancer (Rodriguez *et al.* 2007, Zhang *et al.* 2015). Furthermore, multiple large studies, both before and after the introduction of widespread PSA screening in the U.S., demonstrated an association between obesity and increased prostate cancer-specific mortality (Andersson *et al.* 1997, Rodriguez *et al.* 2001, Wright *et al.* 2007, Cao & Ma 2011, Zhang *et al.* 2015), indicating that obesity-associated detection bias does not

completely explain the association between obesity and prostate cancer, but that biologic mechanisms must also play a role.

Consistent with epidemiologic evidence for an association between obesity and tumor aggressiveness and progression, tumor growth in mouse models of prostate cancer has been shown to be responsive to obesity. A number of studies have demonstrated a role for diet-induced obesity in promoting prostate tumor growth in the transgenic adenocarcinoma of the prostate (TRAMP) mouse model (Llaverias *et al.* 2010, Bonorden *et al.* 2012). In addition, diet-induced obesity reduced tumor latency in the Hi-Myc mouse model, via increased Akt/mTOR signaling (Kobayashi *et al.* 2008, Blando *et al.* 2011), and promoted tumor progression in a transgenic mouse model with PTEN haploinsufficiency, via increased inflammatory and insulin signaling pathways (Liu *et al.* 2015). These transgenic models may have relevance to the human prostate cancer, given that the Myc copy number is amplified in up to one third of human prostate cancers (Ellwood-Yen *et al.* 2003) and PTEN loss is the most common genetic alteration in human prostate cancer (Wang *et al.* 2003).

Non-biologic mechanisms contributing to the obesity – cancer link

Obesity and cancer screening

Evidence suggests that obesity-associated screening and detection biases may act to delay cancer diagnosis, thereby increasing cancer-specific mortality in obese patients

(Fig. 2). Obese individuals may be less likely to participate in screening programs, which could contribute to delayed cancer diagnosis, an association shown to be modified by the type of screening test, by race and by gender (Fagan *et al.* 2011). Indeed, mammography screening rates are reduced by as much as 10% in obese (BMI ≥ 30 kg/m²) and 20% in morbidly obese (BMI ≥ 40 kg/m²) women (Maruthur *et al.* 2009), and while the reasons for reduced participation in cancer screening are not completely understood, they may include modesty, pain, and/or competing healthcare demands (Friedman *et al.* 2012).

In contrast to the associations with breast cancer screening, an inverse association between obesity and PSA screening frequency has been reported in prostate cancer, with obese men being screened more frequently than their normal-weight counterparts (Scales *et al.* 2007). However, obesity is associated with a reduced likelihood of prostate cancer diagnosis in a screened population despite higher PSA screening frequency in obese men, suggesting that obesity may decrease screening effectiveness in some cancer types. In obese prostate cancer patients, their larger body size and bigger prostate make conducting a digital rectal exam more challenging (Chu *et al.* 2011), and a large prostate may reduce the likelihood of finding the cancer at biopsy (Freedland *et al.* 2006). This is also true for other cancer types; mammography is anecdotally more difficult in obese patients (Amy *et al.* 2006), potentially delaying cancer diagnosis even in screened obese individuals. Indeed, obesity has been associated with a higher stage at breast cancer diagnosis (Cui *et al.* 2002), suggesting that obese women may be diagnosed later in the course of their disease. However, another study reported this finding

Figure 2

Non-biologic mechanisms linking obesity and cancer mortality.

regardless of mammography screening frequency, suggesting that the association between obesity and high-stage breast cancer may not simply be a result of lower screening rates in this population (Kerlikowske *et al.* 2008), but that biologic mechanisms must also play a role.

Finally, the larger blood volume in obese individuals has been associated with biomarker hemodilution, as has been suggested in PSA-detected prostate cancer (Banez *et al.* 2007). Several studies have estimated that PSA levels are reduced by ~15% in cancer-free morbidly obese (BMI ≥ 35 kg/m²) men, while PSA mass (i.e., the absolute quantity of PSA in the blood) is not associated with obesity status (Grubb *et al.* 2009, Rundle & Neugut 2009). Lower biomarker levels in obesity reduce the likelihood of reaching biopsy thresholds, potentially contributing to delayed diagnosis in obese individuals.

Obesity and cancer treatment

In addition to biologic mechanisms (reviewed in Lashinger *et al.* (2014b)), non-biologic factors also contribute to the reduced treatment efficacy in obese patients (Fig. 2). There is considerable evidence to suggest that obese cancer patients are undertreated with systemic therapies (Lyman & Sparreboom 2013), and this may negatively impact cancer outcomes. Traditionally, chemotherapy dosing is based upon the body surface area (BSA) of the patient. However, there is uncertainty regarding dosing of obese patients and evidence that dose reduction occurs in this population, either because an idealized body weight is used to calculate BSA, or because BSA is arbitrarily capped due to toxicity concerns (Lyman *et al.* 2003). Current clinical guidelines for chemotherapy dosing in obese patients indicate that weight-based chemotherapy doses should be given and that dose should not be reduced for obese patients (Griggs *et al.* 2012). As such, it is recommended that any modifications to the dose due to toxicity concerns or presence of co-morbidities should be made independently of the patient's obesity status (Lyman & Sparreboom 2013).

In prostate cancer, obesity is associated with increased daily prostate shift, rendering external beam radiation treatment more technically challenging, and potentially contributing to increased rates of treatment failure in obese patients (Merrick *et al.* 2007). Technical difficulties applying the adequate radiation dose to the correct area in obese patients has also been suggested in breast cancer (Carmichael & Bates 2004). In addition to these potential difficulties with radiation therapy, obese patients may also be less likely to make good surgical candidates. In prostate

cancer, obesity has been shown to be associated with capsular incision, reflecting a less-than-ideal operation (Freedland *et al.* 2005). However, even when focusing solely on patients with organ-confined disease and negative surgical margins, obesity remains associated with biochemical recurrence following radical prostatectomy, implying that obesity is associated with disease progression in prostate cancer through mechanisms other than how it may affect surgical technique (Freedland *et al.* 2004).

Obesity and related co-morbidities are associated with an increased risk of adverse treatment effects, which may impact the treatment plan (Schmitz *et al.* 2013). In breast cancer, obesity has been associated with a higher risk of lymphedema, in addition to other treatment-related side effects (Togawa *et al.* 2014). Obese, diabetic breast cancer patients undergoing chemotherapy have increased likelihood of side effects, including infection and chemotherapy-related toxicity (Srokowski *et al.* 2009). In addition, cytotoxic therapy has been associated with treatment-related weight gain and metabolic syndrome in breast cancer patients (Bicakli *et al.* 2014, Makari-Judson *et al.* 2014), potentially exacerbating these aforementioned side effects. In prostate cancer, obesity is associated with weight gain and increased risk of diabetes following androgen deprivation therapy (Keto *et al.* 2011, Tsai *et al.* 2014), particularly among older men (Morgans *et al.* 2014). Given that more men diagnosed with prostate cancer die from cardiovascular disease than from prostate cancer (Allott *et al.* 2013a), this relationship has important implications for prostate cancer survivors.

Finally, excess body weight has been linked to altered metabolism of cytotoxic drugs and therapies, potentially via a number of mechanisms, including altered levels of circulating growth factors, hormones and cytokines (Rodvold *et al.* 1988, Litton *et al.* 2008). Despite evidence that aromatase inhibitors may not be as efficacious in obese breast cancer patients (Wolters *et al.* 2012, Azrad & Demark-Wahnefried 2014, Ioannides *et al.* 2014), standard doses are given irrespective of BSA or body size (Goodwin & Pritchard 2010). In contrast, response to tamoxifen has not been shown to differ by obesity status (Wolters *et al.* 2012), and no differences in ER-positive breast cancer recurrence rates by obesity status have been reported following tamoxifen treatment (Dignam *et al.* 2003). Finally, one trial suggested that obese breast cancer patients treated with chemotherapy had reduced disease-free survival relative to normal weight patients, even after controlling for other prognostic factors (de Azambuja *et al.* 2010). In prostate cancer, obesity at the time of androgen

deprivation therapy is associated with an increased risk of castrate-resistant prostate cancer, metastasis and prostate cancer-specific mortality (Keto *et al.* 2011). Although the exact explanation for this is unclear, one study found that testosterone levels in obese men on androgen deprivation therapy were higher, suggesting inadequate testosterone suppression (Smith 2007). It has been hypothesized that this may be because the amount of gonadotropin-releasing hormone analogue given is the same regardless of BSA, and thus obese men may be under-dosed. However, while these non-biological factors must be considered, they cannot completely explain the association between obesity and cancer mortality, and biologic mechanisms must also contribute (Lashinger *et al.* 2014b).

Obesity and related co-morbidities as modifiable lifestyle factors

Weight gain and loss

Evidence for the association between obesity and cancer is substantiated by studies showing that weight change can impact both risk and survival for obesity-associated cancers (Fig. 3). Bariatric procedures to cause weight loss have been associated with reduced risk of obesity-associated cancer types and a 40–50% decrease in cancer-specific mortality across cancer types (Sjostrom *et al.* 2007, Adams *et al.* 2009), suggesting that weight loss may be an

effective chemopreventive strategy in obese individuals (Ashrafi *et al.* 2011). Interestingly, one prospective intervention trial suggested that bariatric procedures may be more effective at decreasing cancer risk in women, compared to men (Sjostrom *et al.* 2009), although these results should be interpreted with caution given the smaller sample size of males and mean follow-up time of only one decade, which may not be a long enough latency period for certain cancer types to manifest (Renehan 2009). Aside from these studies of bariatric patients, the majority of the evidence supporting a role for weight change in cancer incidence and mortality comes from secondary analyses of observational studies. Of note, the most common pattern of weight change over time is consistent weight gain throughout adulthood (Harvie *et al.* 2005), and therefore statistical power to study the impact of weight loss is often limited.

Adult weight gain is associated with increased risk of postmenopausal breast cancer (Eliassen *et al.* 2006), with a suggestion of a stronger association for hormone receptor-positive breast cancer (Eliassen *et al.* 2006, Vrieling *et al.* 2010). Furthermore, adult weight gain prior to diagnosis is associated with increased mortality from postmenopausal breast cancer (Cleveland *et al.* 2007). Conversely, weight loss during adulthood, whether before or after menopause, has been associated with decreased risk of postmenopausal breast cancer (Harvie *et al.* 2005, Eliassen *et al.* 2006), again with the strongest inverse associations for hormone receptor-positive breast cancer (Eliassen *et al.* 2006). While clinical trials to formally examine the impact of weight loss on breast cancer-specific mortality have not yet been conducted, two trials in breast cancer survivors reported that weight loss of >10% of body mass can be achieved in this population (Befort *et al.* 2012, Goodwin *et al.* 2014). Furthermore, a weight loss intervention in cancer-free postmenopausal women suggested that 10% weight loss is sufficient to positively impact biomarker levels associated with breast cancer in both serum and benign breast tissue (Fabian *et al.* 2013), indicating that such an intervention may be both feasible and worthwhile (Irwin 2014).

Evidence from mouse models of breast cancer showing that weight loss impacts tumor growth supports these epidemiologic data. Weight loss can be achieved in mouse models by calorie restriction (CR), a 20–40% reduction in total energy intake relative to a control group fed *ad libitum*, arguably one of the most potent dietary regimens for suppressing carcinogenesis (Hursting *et al.* 2010). Despite the suggestion of stronger epidemiologic associations between weight change and hormone

Figure 3

Putative mechanisms linking obesity with cancer risk and progression: lessons from studies of chemopreventive agents.

receptor-positive breast cancer, CR slows tumor growth in mouse models regardless of tumor subtype (Pape-Ansorge *et al.* 2002, Dunlap *et al.* 2012, Nogueira *et al.* 2012, Ford *et al.* 2013b, Mizuno *et al.* 2013), providing rationale to study the impact of weight loss across breast cancer subtypes in humans. Mechanistic insights from these models have highlighted Akt/mTOR signaling and the insulin/insulin-like growth factor (IGF) 1 axis as two pro-tumor pathways upregulated by obesity and reversed by CR (Hursting *et al.* 2010). Interestingly, a protective effect of intermittent CR on tumor growth has also been reported (Rogozina *et al.* 2013), and this dietary regimen may be more feasible and appealing to humans. While the majority of preclinical studies randomize mice to CR from the outset, two preclinical studies have specifically tested the impact of diet-induced obesity followed by weight loss, by incorporating a diet switch during the intervention period. Interestingly, these studies reported contrasting findings, with one reporting that weight loss reversed the tumor-promoting effect of obesity (Sundaram *et al.* 2014a), and the other reporting that weight loss did not impact obesity-fueled tumor growth (De Angel *et al.* 2013). Key differences between studies included the degree of obesity attained by the mice and the timing and duration of weight loss, in addition to the use of two different mouse models of basal-like breast cancer, one xenograft (De Angel *et al.* 2013) and the other transgenic (Sundaram *et al.* 2014a). Discrepant findings such as these may shed light on mechanisms linking weight loss and breast cancer, in addition to informing future study design in both preclinical mouse models and humans.

Retrospective analyses of large cohort studies have also revealed inverse associations between weight loss and prostate cancer incidence and mortality. Relative to weight maintenance, adult weight gain is associated with an increased risk of aggressive prostate cancer (Bassett *et al.* 2011), while adult weight loss is associated with reduced risk of aggressive prostate cancer (Rodriguez *et al.* 2007). Furthermore, some large prospective cohort studies have reported that weight gain in adulthood is associated with increased prostate cancer-specific mortality (Wright *et al.* 2007, Bassett *et al.* 2011), although others reported no association between adult weight change and prostate cancer-specific mortality (Chamberlain *et al.* 2011, Moller *et al.* 2013). Studies focused on weight change within the decade of prostate cancer diagnosis report more consistent findings, with weight gain in the 5-year time period preceding diagnosis associated with increased risk of recurrence (Joshu *et al.* 2011, Whitley *et al.* 2011), and weight gain in the 5-year time period following diagnosis

associated with an increased risk of prostate cancer-specific mortality (Bonn *et al.* 2014).

While evidence for a role for weight loss in counter-acting tumor growth in mouse models of prostate cancer is relatively sparse, a tumor-inhibitory effect of CR has been demonstrated via reduced insulin/IGF1 levels and increased tumor apoptosis in a xenograft mouse model (Galet *et al.* 2013), although this effect has not been reported in all xenograft models (Buschemeyer *et al.* 2010, Thomas *et al.* 2010). In addition, one study demonstrated that CR slowed progression to adenocarcinoma in the Hi-Myc transgenic mouse model of prostate cancer, via reduced prostate inflammation and inhibition of Akt/mTOR signaling (Blando *et al.* 2011). CR has also been demonstrated to impact tumor growth in the TRAMP model, with intermittent CR having a greater impact than chronic CR (Bonorden *et al.* 2009), although a role for intermittent CR has not been supported by other prostate cancer studies (Buschemeyer *et al.* 2010, Thomas *et al.* 2010).

Given the challenges surrounding compliance with CR and maintenance of weight loss in humans, alternative strategies are also worth exploring. Intermittent CR is one such strategy, and while one randomized weight loss trial in women showed that both intermittent and chronic CR caused weight loss and improved insulin sensitivity and cytokine profile (Harvie *et al.* 2011), avoiding weight gain may remain the most sensible approach both for general health and chemoprevention (Thompson & McTiernan 2011). Alternatively, understanding the mechanisms by which CR increases tumor latency and slows tumor progression may help identify CR mimetics with chemopreventive properties (reviewed in (Hursting *et al.* 2010)).

Pharmaceuticals

Type II diabetes and metformin Type II diabetes currently affects ~15% of the adult population in the U.S., and the prevalence of this obesity-associated co-morbidity is on the increase (Boyle *et al.* 2010). Epidemiologic data support an association between diabetes and an increased risk of certain cancer types, including breast cancer (Larsson *et al.* 2007, Giovannucci *et al.* 2010, De Brujin *et al.* 2013, Tsilidis *et al.* 2015a). Although not all studies have reported subtype-specific differences in this association (Campos-Gomez *et al.* 2014), there is some evidence that the association between diabetes and breast cancer risk may be stronger in postmenopausal women (Michels *et al.* 2003, Larsson *et al.* 2007) and for hormone receptor-positive breast cancer (Michels *et al.* 2003). In addition,

a meta-analysis of clinical trials and prospective cohort studies reported that diabetes is associated with increased breast cancer-specific mortality, although subtype was not examined (De Bruijn *et al.* 2013). In direct contrast to the positive association with breast cancer risk, there is an inverse association between diabetes and total prostate cancer incidence (Kasper & Giovannucci 2006, Zhang *et al.* 2012). Temporal analysis has demonstrated that longer duration of diabetes is more protective for total prostate cancer risk (Kasper *et al.* 2009, Tsilidis *et al.* 2015b), suggesting that the metabolic and hormonal environment of advanced/end-stage diabetes, characterized by reduced bioavailable testosterone and low insulin, is consistent with protection from total prostate cancer incidence (Kasper & Giovannucci 2006, Allott *et al.* 2013b). However, longer duration of diabetes in obese men was associated with increased risk of metastasis following radical prostatectomy (Wu *et al.* 2013), and diabetes has been associated with an increased risk of prostate cancer-specific mortality (Cai *et al.* 2014), suggesting that the low-insulin environment of advanced diabetes may select for more aggressive prostate cancers that can survive in this environment (Allott *et al.* 2013b). Therefore, while associations with diabetes are contrasting for breast and prostate cancer incidence, associations with cancer progression and mortality are consistent for both tumor types.

Relative to other anti-diabetic therapies, metformin has been associated with reduced total cancer incidence in some (Evans *et al.* 2005, Decensi *et al.* 2010), but not all studies (Tsilidis *et al.* 2014), and with decreased cancer-specific mortality (Currie *et al.* 2012, Lega *et al.* 2014). In line with these findings, evidence supporting a role for metformin in breast cancer is somewhat mixed. A meta-analysis reported that metformin use was associated with reduced breast cancer incidence and mortality (Zhang *et al.* 2013), but other studies failed to demonstrate a protective effect of metformin on breast cancer incidence (Franciosi *et al.* 2013, Tsilidis *et al.* 2014, Kowall *et al.* 2015) or mortality (Lega *et al.* 2014). Furthermore, there is inconsistent evidence for differences in these associations by breast cancer subtype, with one study reporting a larger proportion of progesterone receptor-positive tumors in metformin users vs non-users (Berstein *et al.* 2011), while another study did not find any difference in the frequency of hormone receptor-positive tumors by metformin use (Besic *et al.* 2014). A trial in which women were randomized to metformin 1 month prior to breast cancer surgery found that metformin use reduced Ki67 expression in HER2-positive resected tumors (DeCensi *et al.* 2014), while another study reported that metformin use was

associated with reduced HER2-positive breast cancer-specific mortality (He *et al.* 2012). In support of these epidemiologic data, preclinical data show that metformin suppressed overexpression of the HER2 protein via Akt/mTOR pathway inhibition (Vazquez-Martin *et al.* 2009), and delayed the onset of adenocarcinoma in a transgenic mouse model of HER2-positive breast cancer (Anisimov *et al.* 2010). However, metformin has also been shown to slow tumor growth in an ER-positive mouse model of breast cancer, via suppression of obesity-associated adipokine levels and reduced Akt/mTOR pathway activation (Fuentes-Mattei *et al.* 2014), suggesting that the potential chemopreventive effect of metformin may not be limited to HER2-positive tumors. Finally, a preclinical study reported that metformin does not impact tumor growth in nondiabetic rat and mouse models (Thompson *et al.* 2015), a finding supported by epidemiologic data that metformin impacts Ki67 tumor expression in insulin-resistant but not in insulin-sensitive women (DeCensi *et al.* 2014).

In prostate cancer, although some studies report inconsistent findings (Murtola *et al.* 2008, Currie *et al.* 2009, Wright & Stanford 2009, Azoulay *et al.* 2011, Franciosi *et al.* 2013), mounting evidence supports an inverse association between metformin use and prostate cancer risk in men with diabetes (Clyne 2014, Preston *et al.* 2014, Yu *et al.* 2014a). Fewer studies have examined the association between metformin use and prostate cancer recurrence and mortality, with somewhat mixed results. While several individual studies reported null findings (Patel *et al.* 2010, Allott *et al.* 2013b, Kaushik *et al.* 2013), a meta-analysis demonstrated that metformin use was associated with reduced risk of recurrence following primary therapy (Yu *et al.* 2014a), and there is evidence to support an inverse association between metformin use and prostate cancer-specific mortality (Margel *et al.* 2013, Bensimon *et al.* 2014), although this has not been reported by all studies (Lega *et al.* 2014). Further supporting a chemopreventive role for metformin in prostate cancer, metformin slowed tumor growth in a xenograft mouse model of prostate cancer (Ben Sahra *et al.* 2008), in addition to reducing IGF1 levels and modestly counteracting the tumor-promoting properties of a high-fat diet in a small study using the TRAMP model (Xu *et al.* 2014). Finally, metformin reduced mouse prostatic intraepithelial neoplasia (mPIN) development and slowed transition to adenocarcinoma in the Hi-Myc transgenic mouse model of prostate cancer, via downregulation of *Myc* gene expression (Akinyeke *et al.* 2013).

While data from both preclinical and population-based studies support an antineoplastic role for metformin, translating findings from laboratory studies to humans is rendered more challenging by high metformin doses commonly used in animal and cell-based models, often exceeding recommended therapeutic doses in humans (Ben Sahra *et al.* 2010). In addition, the progressive nature of diabetes and the various medications used to control it makes population-based research into the impact of metformin on cancer risk and mortality somewhat challenging. Time-related biases are a consideration in observational studies of drug use and may lead to overestimation of the inverse association between metformin and cancer (Suijsa & Azoulay 2012). However, a meta-analysis of prospective studies that controlled for obesity status and that were not subject to time-related biases concluded that metformin was associated with a modest reduction in overall cancer risk (Gandini *et al.* 2014). Whether metformin should be considered as a chemopreventive agent for individuals without diabetes is another issue. Preclinical studies have demonstrated direct action of metformin on cancer cells through AMPK activation and mTOR signaling (Zhou *et al.* 2001, Hardie & Alessi 2013), suggesting that metformin may also have chemopreventive properties in individuals without insulin resistance or diabetes. However, a body of evidence in both population and preclinical mouse models suggests that metformin impacts tumor growth only in the context of insulin resistance, obesity and/or diabetes, indicating that improving insulin sensitivity may be a key indirect mechanism by which metformin impacts cancer growth (Bonanni *et al.* 2012, DeCensi *et al.* 2014, Thompson *et al.* 2015). This proposed mechanism is further supported by evidence linking elevated levels of C-peptide (a surrogate for insulin levels) with breast and prostate cancer-specific mortality (Ma *et al.* 2008, Goodwin *et al.* 2012). Therefore, while evidence suggests that metformin may be most beneficial for preventing cancer growth in insulin-resistant individuals via indirect mechanisms, future studies should explore potential direct mechanisms using preclinical models and metformin doses that reflect those used in humans.

Inflammation and non-steroidal anti-inflammatory drugs Chronic, low-grade inflammation is a hallmark of obesity, and has been proposed as a mechanistic link between obesity and cancer (Colotta *et al.* 2009). Metabolism of arachidonic acid, a major component of animal fat, by cyclooxygenase (COX) generates prostaglandin and other eicosanoids, a group

of biologically active lipids that play a key role in inflammation. Obesity is associated with elevated levels of COX-2 expression and heightened prostaglandin signaling (Subbaramaiah *et al.* 2012), suggesting a targetable inflammatory mechanism linking obesity and cancer. The anti-inflammatory properties of non-steroidal anti-inflammatory drugs (NSAIDs) are mediated via COX inhibition, which in turn reduces prostaglandin levels (Wang & Dubois 2010). While the strongest evidence for a role for NSAIDs in chemoprevention comes from inverse associations with adenoma and colorectal cancer (Baron *et al.* 2003, Rostom *et al.* 2007), there is also support for a role for NSAIDs in other cancer types (Wang & Dubois 2010).

While normal breast tissue expresses low levels of COX-2, ~40% of invasive breast cancers overexpress this enzyme, and elevated levels are associated with increased risk of breast cancer-specific mortality (Ristimäki *et al.* 2002). The inverse association between NSAID use and breast cancer incidence does not appear to differ significantly by drug type, with similar effect estimates reported for both aspirin and non-aspirin NSAIDs (de Pedro *et al.* 2015). However, a randomized trial of low-dose aspirin failed to demonstrate an inverse association for breast cancer incidence (Cook *et al.* 2005), potentially suggesting that a higher dose may be required for chemoprevention. Some studies report that the protective association between NSAID use and breast cancer is limited to hormone receptor-positive disease (Terry *et al.* 2004, de Pedro *et al.* 2015), and others have reported a stronger inverse association between NSAID use and breast cancer-specific mortality in hormone receptor-positive cases (Allott *et al.* 2014a). Given that COX-2-mediated prostaglandin production promotes estrogen biosynthesis via upregulation of the aromatase pathway (Zhao *et al.* 1996), there is biologic rationale to support a role for NSAIDs in suppressing hormone receptor-positive breast cancer incidence and progression. Indeed, NSAID use is associated with reduced serum estradiol levels in women with breast cancer (Hudson *et al.* 2008), which may impact the growth of estrogen-responsive tumors. Finally, in further support of a true biologic association between NSAID use and breast cancer, there is evidence that longer duration of NSAID use is more protective for both breast cancer incidence (Terry *et al.* 2004) and breast cancer-specific mortality (Allott *et al.* 2014a).

Studies in breast cancer mouse models support a role for COX-2 in promoting tumor growth (Liu *et al.* 2001, Lyons *et al.* 2011) and for selective COX-2 inhibitors, including celecoxib, in inhibiting tumor growth

(Chang *et al.* 2004). One study showed that celecoxib was most protective in HER2-expressing mouse models of breast cancer, via reduction of prostaglandin levels (Howe *et al.* 2002), indicating a potential role for COX-2 inhibition in preventing HER2-positive breast cancer. However, while COX-2 overexpression has been reported in HER2-positive breast cancers in women (Ristimäki *et al.* 2002, Subbaramaiah *et al.* 2002), the impact of NSAID use on this tumor subtype has not been widely examined, perhaps due to the relatively low frequency of HER2-enriched breast cancers in the human population. Finally, a study in a rat model of breast cancer showed that NSAIDs were only effective in hormone-responsive tumors (Woditschka *et al.* 2008), supporting epidemiologic literature reporting stronger associations between NSAID use and hormone receptor-positive breast cancer risk and mortality.

Similar to breast cancer, there is evidence for overexpression of COX-2 in prostate cancer, relative to non-cancerous tissue or benign prostatic hyperplasia (Yoshimura *et al.* 2000), and elevated expression is associated with increased prostate cancer-specific mortality (Khor *et al.* 2007). A meta-analysis reported an inverse association between NSAID use and aggressive prostate cancer risk, which was strongest among aspirin users, particularly longer-duration aspirin users (Liu *et al.* 2014). However, a randomized trial of celecoxib for 4–6 weeks in patients with localized prostate cancer had no impact on prostaglandin levels in the prostate (Antonarakis *et al.* 2009), potentially suggesting an exposure period of insufficient length to impact prostate cancer biology. Interestingly, the association between aspirin use and aggressive prostate cancer incidence appears to differ by geographic region, with a significant protective effect evident in North American but not in European studies (Liu *et al.* 2014, Wang *et al.* 2014). Given that anti-inflammatory agents such as NSAIDs can lower PSA levels (Chang *et al.* 2010), this geographic disparity in results may be attributable in part to differences in screening practices. However, one North American study where prostate cancer screening was largely independent of PSA testing reported that aspirin and NSAID use was associated with reduced risk of aggressive disease (Vidal *et al.* 2014), supporting a true biologic association between NSAID use and prostate cancer. Finally, a number of studies in the TRAMP mouse model of prostate cancer support a role for COX inhibition in prostate cancer chemoprevention, reporting that celecoxib reduced tumor size (Gupta *et al.* 2004), caused regression of mPIN lesions (Narayanan *et al.* 2004) and inhibited the development of adenocarcinoma in a dose-dependent fashion (Narayanan *et al.* 2006).

One limitation of many observational studies of NSAID use is incomplete capture of NSAID use information, with many studies focusing solely on aspirin or ibuprofen use, or on prescription NSAIDs only (Allott *et al.* 2014a, de Pedro *et al.* 2015). Incomplete NSAID use data may attenuate the association between NSAID use and cancer, since ‘unexposed’ individuals may have taken other types of NSAIDs that were not ascertained during data collection, especially given the widespread use of these drugs. In addition, confounding by indication is an important consideration in observational studies of NSAID use, as users may be more likely to have chronic conditions such as arthritis for which they are taking NSAIDs (Allott *et al.* 2014a). Finally, although epidemiologic and preclinical evidence supports a role for COX inhibition in chemoprevention, the clinical utility of selective COX-2 inhibitors is limited due to cardiovascular and gastrointestinal side effects (Wang & Dubois 2010). As such, understanding the mechanisms linking NSAID use and cancer will result in the identification of additional biomarkers and therapeutic targets, potentially enabling the development of therapeutic agents with fewer side effects than existing COX inhibitors.

Hypercholesterolemia and statins Hypercholesterolemia, an obesity-associated co-morbidity, affects ~20% of the U.S. adult population (Fryar *et al.* 2012). Cholesterol is an essential plasma membrane component of animal cells and plays a crucial role in maintaining membrane fluidity, in addition to regulating intracellular signaling processes (Krycer & Brown 2013). The role of cholesterol as the precursor for endogenous sex steroid biosynthesis suggests its potential importance in both breast and prostate cancer, two hormone-dependent tumor types.

Dietary cholesterol intake is associated with increased risk of breast cancer, with evidence for a dose-dependent effect across increasing quartiles of cholesterol intake (Hu *et al.* 2012). Moreover, a large prospective study of over one million adults in Korea showed that serum cholesterol levels were associated with increased risk of breast cancer (Kitahara *et al.* 2011). Consistent with the role of cholesterol as a precursor for sex steroid biosynthesis, studies that stratified by hormone receptor status reported that elevated serum cholesterol levels were associated with increased risk of hormone receptor-positive disease (Fagherazzi *et al.* 2010) and that high dietary cholesterol intake was associated with increased risk of ER-positive, but not ER-negative disease (Jakovljevic *et al.* 2002). Finally, a recent study demonstrated that 27-hydroxycholesterol (27-HC), the most abundant cholesterol

metabolite in the circulation and an endogenous selective ER modulator (SERM), promoted ER-positive breast cancer progression in multiple mouse models (Nelson *et al.* 2013), suggesting a mechanistic link between cholesterol and breast cancer.

Relative to other organs of the body, normal prostate epithelial cells have high cholesterol content, and these levels increase further during progression to prostate cancer (Krycer & Brown 2013), suggesting that cholesterol accumulation may be advantageous to prostate cancer progression. In support of this hypothesis, hypermethylation of the cholesterol efflux transporter ABCA1, an epigenetic silencing mechanism leading to accumulation of intratumoral cholesterol, has been associated with increased risk of aggressive prostate cancer (Lee *et al.* 2013). There is a suggestion that elevated cholesterol may be associated with increased risk of aggressive prostate cancer (Platz *et al.* 2008, Platz *et al.* 2009, Farwell *et al.* 2011, Mondul *et al.* 2011, Shafique *et al.* 2012) but not total prostate cancer (Platz *et al.* 2008, Mondul *et al.* 2010), although other studies have reported no association between cholesterol or its sub-fractions and prostate cancer risk (Martin *et al.* 2009, Jacobs *et al.* 2012). While studies examining prostate cancer progression are few, positive associations between elevated serum cholesterol levels and risk of prostate cancer recurrence (Allott *et al.* 2014b) and mortality (Batty *et al.* 2011) have been reported. In support of these epidemiologic associations, cholesterol has been shown to promote prostate cancer cell line growth *in vitro* and *in vivo* (Zhuang *et al.* 2002), while reduction of serum cholesterol levels lowered intratumoral androgen levels and slowed tumor growth in xenograft mouse models of human prostate cancer (Mostaghel *et al.* 2012), supporting the hypothesis that steroid biosynthesis may be an important mechanism linking cholesterol and prostate cancer.

Statins are cost-effective and widely prescribed cholesterol-lowering drugs with proven benefits for cardiovascular disease prevention (Ridker & Cook 2013), and are used by approximately one in every four adults in the U.S. population (Gu Q 2014). Statin use has been associated with reduced total cancer risk (Farwell *et al.* 2008) and lower cancer-specific mortality (Nielsen *et al.* 2012) via a number of potential mechanisms including mevalonate pathway inhibition (Pelton *et al.* 2012), reduced inflammation and angiogenesis (Pelton *et al.* 2012) and lower serum cholesterol levels (Demierre *et al.* 2005). Given that the bioavailability of statins in the circulation is low (Roy *et al.* 2011), their cholesterol-lowering properties may be the most relevant for breast and prostate cancers.

Despite biologic rationale for a role of statins in breast cancer chemoprevention, the majority of evidence supports no association between statin use and total breast cancer risk (Bonovas *et al.* 2005, Undela *et al.* 2012), and studies examining this association by breast cancer subtype are few. While one study reported reduced rates of ER-negative breast cancers among statin users (Kumar *et al.* 2008), another found a null association overall and no evidence of effect modification by hormone receptor status (Desai *et al.* 2013). However, epidemiologic evidence supports an inverse association between statin use and risk of breast cancer recurrence and mortality. Statin use after a breast cancer diagnosis has been associated with reduced risk of recurrence, with a stronger association for lipophilic statins (Kwan *et al.* 2008, Ahern *et al.* 2011). Furthermore, a study of over 30 000 breast cancer cases in the Finnish Cancer Registry showed an inverse effect of both pre and post-diagnosis statin use on breast cancer-specific mortality, with evidence for a dose and time-dependent effect among pre-diagnosis users (Murtola *et al.* 2014). Another study in the UK Cancer Registry also reported a weak protective effect of statin use on breast cancer-specific mortality, with some evidence that simvastatin use showed the strongest association (Cardwell *et al.* 2015). Studies stratifying by hormone receptor status are required, as this information has been lacking in previous studies (Murtola *et al.* 2014, Cardwell *et al.* 2015).

In prostate cancer, while the preponderance of evidence does not support an association between statin use and total prostate cancer risk (Dale *et al.* 2006, Browning & Martin 2007, Bonovas *et al.* 2008, Kuoppala *et al.* 2008, Bansal *et al.* 2012), an inverse association between statin use and risk of aggressive disease has been consistently reported (Bonovas *et al.* 2008, Bansal *et al.* 2012). Regarding prostate cancer outcomes after treatment, three meta-analyses have reported a null association between statin use and risk of recurrence (Mass *et al.* 2012, Park *et al.* 2013, Scosyrev *et al.* 2013). However, the studies contributing to these meta-analyses were few and most examined statin use at the time of prostate cancer treatment. Given the widespread use of statins, it is likely that many nonusers became statin users after treatment, which may bias the results of these previous studies towards the null. A retrospective analysis that minimized misclassification of statin users by excluding prevalent users at the time of prostate cancer treatment and capturing statin use throughout the follow-up period showed that post-diagnosis statin use was associated with reduced risk of recurrence (Allott *et al.* 2014c), suggesting

a true protective association between statin use and prostate cancer. Finally, an analysis of almost 12 000 men with localized prostate cancer showed that post-diagnostic statin use was associated with reduced prostate cancer-specific mortality, with evidence for a stronger protective effect among those who had also used statins before diagnosis (Yu *et al.* 2014b). Given that cardiovascular disease and cancer are the two most common causes of mortality in the U.S. (American Society of Clinical 2014), understanding the potential role of cholesterol reduction for cancer prevention will have important public health impact.

Transdisciplinary challenges facing obesity and cancer research

Obesity is a complex and heterogeneous exposure, giving rise to a number of considerations and challenges for obesity and cancer research, particularly in translating findings from preclinical to population-based research, and *vice versa*.

First, inter-individual variation in adipose tissue distribution leads to challenges in defining obesity status for population-based research. BMI is a well-validated surrogate of overall obesity, with the important strength of being widely used, thus enabling inter-study comparisons (Allott *et al.* 2013a). However, visceral obesity – accumulation of adipose tissue within the abdominal cavity – is a risk factor for cardiovascular disease (Neeland *et al.* 2013) and certain types of cancer, including breast and prostate (Pischon *et al.* 2008, Doyle *et al.* 2012). Population-based studies rely on waist circumference and waist-to-hip ratio as surrogates of visceral obesity, given that computed tomography (CT), the gold standard method for direct quantification of visceral fat area (VFA), is not feasible for population-based research. While these surrogate measures correlate more strongly with VFA than BMI does (Allott *et al.* 2014d), it is important to consider that they do not distinguish between subcutaneous and visceral adipose tissue at waist level (Fig. 4), potentially giving rise to some misclassification of visceral obesity status. Despite this limitation, waist circumference and waist-to-hip ratio offer advantages over BMI for estimating visceral obesity, given that these measures are less influenced by lean body mass. Of note, the prevalence of visceral obesity (measured by VFA or waist circumference) in the U.S. population is higher than that of overall obesity (measured by BMI), with ~45% of men and women classified as viscerally obese by VFA (Pou *et al.* 2009), and ~40% of men and 60%

Figure 4

Computed tomography (CT) scans of two individuals with similar waist circumference (WC) but different amounts of visceral and subcutaneous fat area, illustrating the potential for misclassification when using WC as a surrogate of visceral obesity.

of women classified as viscerally obese by waist circumference (Li *et al.* 2007), while only one-third of individuals are classified as obese by BMI (Ogden *et al.* 2014). As such, defining obesity using BMI underestimates the prevalence of visceral obesity in the population. Moreover, roughly 20% of men and 10% of women with BMI ≥ 30 kg/m² do not have elevated VFA, while ~10% of men and women with BMI < 30 kg/m² have elevated VFA (Pou *et al.* 2009). Misclassification of visceral obesity status contaminates the ‘unexposed’ (i.e., non-obese) group with ‘exposed’ individuals (i.e., viscerally obese) and *vice versa*, with the likely result of biasing associations between obesity and cancer towards the null (Fig. 5).

Second, adipose tissue is a unique organ in its ability to expand and contract throughout the life course of the individual, and the relevant timing or ‘window of susceptibility’ for obesity to impact tumor growth is unknown. Furthermore, population-based studies that

Figure 5

Challenges associated with studying obesity: defining the exposure and potential confounders.

examine weight change over the life course are usually limited to self-reported obesity status, and often require individuals to recollect their body weight many decades in the past. However, while self-reported weight is known to be systematically underreported, it remains predictive of obesity-associated co-morbidities and is not outperformed by corrected measures, indicating that it may be sufficient for population-based obesity and cancer research (Dutton & McLaren 2014). Another consideration is that population-based studies of weight change across the life course are limited both by relatively rare occurrences of weight loss and by unknown reasons for weight loss. As such, preclinical models provide an opportunity to evaluate the impact of diet-induced obesity and weight loss at different 'windows of susceptibility' over the life course of the mouse, for example, post pregnancy (Sundaram *et al.* 2014b). Careful design of preclinical studies with a consideration for timing of weight change in relation to tumor development will help to inform research questions in the population-based setting.

Finally, obesity is a heterogeneous phenotype, and it may be useful to consider it a disease comprised of distinct subtypes (Field *et al.* 2013). For example, individuals with elevated BMI may be further stratified according to visceral obesity, diabetes or metabolic syndrome status. This research approach may help us to determine, for example, whether high cholesterol or insulin resistance rather than obesity *per se* are the driving forces behind the obesity-cancer link. Large, population-based studies with sufficient power for stratified analysis by various components of obesity are required for this approach. In addition,

while pharmacoepidemiologic studies provide insight into potential chemopreventive properties of a number of medications that are widely used in the treatment of obesity-associated co-morbidities, these studies are subject to confounding by indication, in addition to other biases inherent in retrospective, observational studies of drug use. As such, results from population-based studies should be interpreted alongside preclinical findings, and alongside randomized controlled clinical trials.

Conclusions

The obesity-cancer link is of public health interest given the pervasiveness of both conditions, and the potentially modifiable nature of obesity. Although calorie restriction and weight loss are some of the most effective approaches for inhibiting tumor growth in animal models, weight loss is challenging for humans to achieve and maintain. Furthermore, observational data supporting a role for weight loss in cancer incidence and mortality in humans are lacking, and neither have clinical trials been conducted. While some epidemiologic and preclinical data suggest a chemopreventive role for agents targeting obesity-associated comorbidities, including metformin, NSAIDs and statins, not all studies support these findings and further research is needed. Given that preclinical models may be limited by their relevance to human cancers and observational studies are limited by non-randomized design, integrating findings from different disciplines using a transdisciplinary approach may help us to gain insight into mechanisms linking obesity and cancer. An improved understanding of the mechanisms contributing to the obesity – cancer link will be important for cancer prevention and treatment efforts. In addition, given that the top five causes of mortality in the U.S. are heart disease, stroke, diabetes, kidney disease and cancer (Schmitz *et al.* 2013), targeting obesity is relevant not only to improve cancer-specific outcomes but also to impact all-cause mortality among cancer survivors.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work was supported by the National Cancer Institute (R35 CA197627, SDH), the Breast Cancer Research Foundation (SDH) and the University Cancer Research Fund of North Carolina (EHA).

References

- Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, Halverson RC, Simper SC, Hopkins PN & Hunt SC 2009 Cancer incidence and mortality after gastric bypass surgery. *Obesity* **17** 796–802. (doi:10.1038/oby.2008.610)
- Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT & Lash TL 2011 Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. *Journal of the National Cancer Institute* **103** 1461–1468. (doi:10.1093/jnci/djr291)
- Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, Yan W, Logan SK & Li X 2013 Metformin targets c-MYC oncogene to prevent prostate cancer. *Carcinogenesis* **34** 2823–2832. (doi:10.1093/carcin/bgt307)
- Allott EH, Masko EM & Freedland SJ 2013a Obesity and prostate cancer: weighing the evidence. *European Urology* **63** 800–809. (doi:10.1016/j.eururo.2012.11.013)
- Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG *et al.* 2013b Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. *Prostate Cancer and Prostatic Diseases* **16** 391–397. (doi:10.1038/pcan.2013.48)
- Allott EH, Tse CK, Olshan AF, Carey LA, Moorman PG & Troester MA 2014a Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. *Breast Cancer Research and Treatment* **147** 415–421. (doi:10.1007/s10549-014-3099-z)
- Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL & Freedland SJ 2014b Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH Database. *Cancer Epidemiology, Biomarkers & Prevention* **23** 2349–2356. (doi:10.1158/1055-9965.EPI-14-0458)
- Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL & Freedland SJ 2014c Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database. *BJU International* **114** 661–666. (doi:10.1111/bju.12720)
- Allott EH, Howard LE, Song HJ, Sourbeer KN, Koontz BF, Salama JK & Freedland SJ 2014d Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy. *Cancer Epidemiology, Biomarkers & Prevention* **23** 2404–2412. (doi:10.1158/1055-9965.EPI-14-0236)
- Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP & Sherman ME 2004 Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. *Cancer Epidemiology, Biomarkers & Prevention* **13** 1558–1568.
- American Society of Clinical Oncology 2014 The state of cancer care in America 2014: a report by the American Society of Clinical Oncology. *Journal of Oncology Practice* **10** 119–142. (doi:10.1200/JOP.2014.001386)
- Amy NK, Aalborg A, Lyons P & Keranen L 2006 Barriers to routine gynecological cancer screening for White and African-American obese women. *International Journal of Obesity* **30** 147–155. (doi:10.1038/sj.ijo.0803105)
- Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A & Nyren O 1997 Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. *Journal of the National Cancer Institute* **89** 385–389. (doi:10.1093/jnci/89.5.385)
- Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin K IV, arkach AS & Romanukha AA 2010 Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors *in vivo*. *Cell Cycle* **9** 188–197. (doi:10.4161/cc.9.1.10407)
- Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Phase *et al.* 2009 randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. *Journal of Clinical Oncology* **27** 4986–4993. (doi:10.1200/JCO.2009.21.9410)
- Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, Ferlay J, Miranda JJ, Romieu I, Ikshitt R *et al.* 2014 Global burden of cancer attributable to high body-mass index in 2012: a population-based study. *Lancet Oncology* **16** 36–46. (doi:10.1016/S1470-2045(14)71123-4)
- Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A & Athanasiou T 2011 Metabolic surgery and cancer: protective effects of bariatric procedures. *Cancer* **117** 1788–1799. (doi:10.1002/cncr.25738)
- de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutierrez J, ndersson M *et al.* 2010 The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. *Breast Cancer Research and Treatment* **119** 145–153. (doi:10.1007/s10549-009-0512-0)
- Azoulay L, Dell'Aniello S, Gagnon B, Pollak M & Suissa S 2011 Metformin and the incidence of prostate cancer in patients with type 2 diabetes. *Cancer Epidemiology, Biomarkers & Prevention* **20** 337–344. (doi:10.1158/1055-9965.EPI-10-0940)
- Azrad M & Demark-Wahnefried W 2014 The association between adiposity and breast cancer recurrence and survival: a review of the recent literature. *Current Nutrition Reports* **3** 9–15. (doi:10.1007/s13668-013-0068-9)
- Banegas JR, Lopez-Garcia E, Gutierrez-Fisac JL, Guallar-Castillon P & Rodriguez-Artalejo F 2003 A simple estimate of mortality attributable to excess weight in the European Union. *European Journal of Clinical Nutrition* **57** 201–208. (doi:10.1038/sj.ejcn.1601538)
- Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr *et al.* 2007 Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. *Journal of the American Medical Association* **298** 2275–2280. (doi:10.1001/jama.298.19.2275)
- Bansal D, Undela K, D'Cruz S & Schifano F 2012 Statin use and risk of prostate cancer: a meta-analysis of observational studies. *PLoS ONE* **7** e46691. (doi:10.1371/journal.pone.0046691)
- Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA *et al.* 2003 A randomized trial of aspirin to prevent colorectal adenomas. *New England Journal of Medicine* **348** 891–899. (doi:10.1056/NEJMoa021735)
- Bassett JK, Severi G, Baglietto L, Macinnis RJ, Hoang HN, Hopper JL, English DR & Giles GG 2011 Weight change and prostate cancer incidence and mortality. *International Journal of Cancer* **131** 1711–1719. (doi:10.1002/ijc.27414)
- Batty GD, Kivimaki M, Clarke R, Davey Smith G & Shipley MJ 2011 Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. *Cancer Causes & Control* **22** 311–318. (doi:10.1007/s10552-010-9691-6)
- Befort CA, Klemp JR, Austin HL, Perri MG, Schmitz KH, Sullivan DK & Fabian CJ 2012 Outcomes of a weight loss intervention among rural breast cancer survivors. *Breast Cancer Research and Treatment* **132** 631–639. (doi:10.1007/s10549-011-1922-3)
- Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y & Bost F 2008 The antidiabetic drug metformin exerts an antitumoral effect *in vitro* and *in vivo* through a decrease of cyclin D1 level. *Oncogene* **27** 3576–3586. (doi:10.1038/sj.onc.1211024)
- Ben Sahra I, Le Marchand-Brustel Y, Tanti JF & Bost F 2010 Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Molecular Cancer Therapeutics* **9** 1092–1099. (doi:10.1158/1535-7163.MCT-09-1186)

- Bensimon L, Yin H, Suissa S, Pollak MN & Azoulay L 2014 The use of metformin in patients with prostate cancer and the risk of death. *Cancer Epidemiology, Biomarkers & Prevention* **23** 2111–2118. (doi:10.1158/1055-9965.EPI-14-0056)
- Bergstrom A, Pisani P, Tenet V, Wolk A & Adami HO 2001 Overweight as an avoidable cause of cancer in Europe. *International Journal of Cancer* **91** 421–430. (doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T)
- Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA & Semiglazov VF 2011 More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. *Medical Oncology* **28** 1260–1263. (doi:10.1007/s12032-010-9572-6)
- Besic N, Satej N, Ratosa I, Horvat AG, Marinko T, Gazic B & Petric R 2014 Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics. *BMC Cancer* **14** 298. (doi:10.1186/1471-2407-14-298)
- Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ali Sanli U & Uslu R 2014 Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. *Journal of Oncology Pharmacy Practice* pii 1078155214551315. (doi:10.1177/1078155214551315)
- Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L, Shen J, Repass J, Strom S & DiGiovanni J 2011 Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. *Cancer Prevention Research* **4** 2002–2014. (doi:10.1158/1940-6207.CAPR-11-0182)
- Bonanni B, Puntoni M, Cazzaniga M, Pruner G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P et al. 2012 Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. *Journal of Clinical Oncology* **30** 2593–2600. (doi:10.1200/JCO.2011.39.3769)
- Bonn SE, Wiklund F, Sjolander A, Szulkin R, Stattin P, Holmberg E, Gronberg H & Balter K 2014 Body mass index and weight change in men with prostate cancer: progression and mortality. *Cancer Causes & Control* **25** 933–943. (doi:10.1007/s10552-014-0393-3)
- Bonorden MJ, Rogozina OP, Kluczny CM, Grossmann ME, Grande JP, Lokshin A & Cleary MP 2009 Cross-sectional analysis of intermittent versus chronic caloric restriction in the TRAMP mouse. *Prostate* **69** 317–326. (doi:10.1002/pros.20878)
- Bonorden MJ, Grossmann ME, Ewing SA, Rogozina OP, Ray A, Nkhata KJ, Liao DJ, Grande JP & Cleary MP 2012 Growth and progression of TRAMP prostate tumors in relationship to diet and obesity. *Prostate Cancer* **2012** article 543970. (doi:10.1155/2012/543970)
- Bonovas S, Filioussi K, Tsavaris N & Sitaras NM 2005 Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. *Journal of Clinical Oncology* **23** 8606–8612. (doi:10.1200/JCO.2005.02.7045)
- Bonovas S, Filioussi K & Sitaras NM 2008 Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. *International Journal of Cancer* **123** 899–904. (doi:10.1002/ijc.23550)
- Borowsky AD 2011 Choosing a mouse model: experimental biology in context – the utility and limitations of mouse models of breast cancer. *Cold Spring Harbor Perspectives in Biology* **3** a009670. (doi:10.1101/cshperspect.a009670)
- Boyle JP, Thompson TJ, Gregg EW, Barker LE & Williamson DF 2010 Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. *Population Health Metrics* **8** 29. (doi:10.1186/1478-7954-8-29)
- Browning DR & Martin RM 2007 Statins and risk of cancer: a systematic review and metaanalysis. *International Journal of Cancer* **120** 833–843. (doi:10.1002/ijc.22366)
- Buschemeyer WC III, Klink JC, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, Cohen P, Hwang D, Johnson TL & Freedland SJ 2010 Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice. *Prostate* **70** 1037–1043. (doi:10.1002/pros.21136)
- Cai H, Xu Z, Xu T, Yu B & Zou Q 2014 Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. *Diabetes/Metabolism Research and Reviews* **31** 336–343. (doi:10.1002/dmrr.2582)
- Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *New England Journal of Medicine* **348** 1625–1638. (doi:10.1056/NEJMoa021423)
- Campos-Gomez S, Valero V, Flores-Arredondo JH, Isassi-Chapa A, Rangel-Rodriguez I, Hortobagyi GN & Gonzalez-Angulo AM 2014 Breast cancer subtype and baseline characteristics from diabetic breast cancer patients are not different from nondiabetics. *Breast Journal* **20** 434–436. (doi:10.1111/tbj.12294)
- Canchola AJ, Anton-Culver H, Bernstein L, Clarke CA, Henderson K, Ma H, Ursin G & Horn-Ross PL 2012 Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. *Cancer Causes & Control* **23** 473–485. (doi:10.1007/s10552-012-9897-x)
- Cao Y & Ma J 2011 Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. *Cancer Prevention Research* **4** 486–501. (doi:10.1158/1940-6207.CAPR-10-0229)
- Cardwell CR, Hicks BM, Hughes C & Murray LJ 2015 Statin use after diagnosis of breast cancer and survival: a population-based cohort study. *Epidemiology* **26** 68–78. (doi:10.1097/EDE.0000000000000189)
- Carmichael AR & Bates T 2004 Obesity and breast cancer: a review of the literature. *Breast* **13** 85–92. (doi:10.1016/j.breast.2003.03.001)
- Centers for Disease Control & Prevention 2011 Cancer survivors–United States, 2007. *MMWR. Morbidity and Mortality Weekly Report* **60** 269–272.
- Chamberlain C, Romundstad P, Vatten L, Gunnell D & Martin RM 2011 The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort. *International Journal of Cancer* **129** 1199–1206. (doi:10.1002/ijc.25739)
- Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R & Norat T 2014 Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. *Annals of Oncology* **25** 1901–1914. (doi:10.1093/annonc/mtu042)
- Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF & Hla T 2004 Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. *PNAS* **101** 591–596. (doi:10.1073/pnas.2535911100)
- Chang SL, Harshman LC & Presti JC Jr 2010 Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. *Journal of Clinical Oncology* **28** 3951–3957. (doi:10.1200/JCO.2009.27.9406)
- Chu DI, De Nunzio C, Gerber L, Thomas JA II, Calloway EE, Alabisinni S, Senocak C, McKeever MG, Moreira DM, Tubaro A et al. 2011 Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. *Prostate Cancer and Prostatic Diseases* **14** 346–353. (doi:10.1038/pcan.2011.31)
- Cleary MP, Grande JP, Juneja SC & Maihle NJ 2004 Diet-induced obesity and mammary tumor development in MMTV-neu female mice. *Nutrition and Cancer* **50** 174–180. (doi:10.1207/s15327914nc5002_7)
- Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI & Gammon MD 2007 Weight gain prior to diagnosis and survival from breast cancer. *Cancer Epidemiology, Biomarkers & Prevention* **16** 1803–1811. (doi:10.1158/1055-9965.EPI-06-0889)
- Clyne M 2014 Prostate cancer: metformin – the new wonder drug? *Nature Reviews. Urology* **11** 366. (doi:10.1038/nrurol.2014.136)
- Colotta F, Allavena P, Sica A, Garlanda C & Mantovani A 2009 Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* **30** 1073–1081. (doi:10.1093/carcin/bgp127)
- Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH & Buring JE 2005 Low-dose aspirin in the primary

- prevention of cancer: the Women's Health Study: a randomized controlled trial. *Journal of the American Medical Association* **294** 47–55. (doi:10.1001/jama.294.1.47)
- Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH & Bush TL 2002 Body mass and stage of breast cancer at diagnosis. *International Journal of Cancer* **98** 279–283. (doi:10.1002/ijc.10209)
- Currie CJ, Poole CD & Gale EA 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia* **52** 1766–1777. (doi:10.1007/s00125-009-1440-6)
- Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA & Morgan CL 2012 Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. *Diabetes Care* **35** 299–304. (doi:10.2337/dc11-1313)
- Dale KM, Coleman CI, Henyan NN, Kluger J & White CM 2006 Statins and cancer risk: a meta-analysis. *Journal of the American Medical Association* **295** 74–80. (doi:10.1001/jama.295.1.74)
- De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA & Hursting SD 2013 The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. *Molecular Carcinogenesis* **52** 446–458. (doi:10.1002/mc.21878)
- De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R & van Eijck CH 2013 Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. *British Journal of Surgery* **100** 1421–1429. (doi:10.1002/bjs.9229)
- Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B & Gandini S 2010 Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. *Cancer Prevention Research* **3** 1451–1461. (doi:10.1158/1940-6207.CAPR-10-0157)
- DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, ofmann U *et al.* 2014 Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. *Breast Cancer Research and Treatment* **148** 81–90. (doi:10.1007/s10549-014-3141-1)
- Demierre MF, Higgins PD, Gruber SB, Hawk E & Lippman SM 2005 Statins and cancer prevention. *Nature Reviews. Cancer* **5** 930–942. (doi:10.1038/nrc1751)
- Desai P, Chlebowski R, Cauley JA, Manson JE, Wu C, Martin LW, Jay A, Bock C, Cote M, etrucelli N *et al.* 2013 Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. *Cancer Epidemiology, Biomarkers & Prevention* **22** 1868–1876. (doi:10.1158/1055-9965.EPI-13-0562)
- Dignam JJ, Wleand K, Johnson KA, Fisher B, Xu L & Mamounas EP 2003 Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. *Journal of the National Cancer Institute* **95** 1467–1476. (doi:10.1093/jnci/djg060)
- Dogan S, Hu X, Zhang Y, Maible NJ, Grande JP & Cleary MP 2007 Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF- α mice. *Breast Cancer Research* **9** R91. (doi:10.1186/bcr1840)
- Doyle SL, Donohoe CL, Lysaght J & Reynolds JV 2012 Visceral obesity, metabolic syndrome, insulin resistance and cancer. *Proceedings of the Nutrition Society* **71** 181–189. (doi:10.1017/S002966511100320X)
- Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L & Hursting SD 2012a Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. *Cancer Prevention Research* **5** 930–942. (doi:10.1158/1940-6207.CAPR-12-0034)
- Dutton DJ & McLaren L 2014 The usefulness of 'corrected' body mass index vs. self-reported body mass index: comparing the population distributions, sensitivity, specificity, and predictive utility of three correction equations using Canadian population-based data. *BMC Public Health* **14** 430. (doi:10.1186/1471-2458-14-430)
- Eliassen AH, Colditz GA, Rosner B, Willett WC & Hankinson SE 2006 Adult weight change and risk of postmenopausal breast cancer. *Journal of the American Medical Association* **296** 193–201. (doi:10.1001/jama.296.2.193)
- Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV & Sawyers CL 2003 Myc-driven murine prostate cancer shares molecular features with human prostate tumors. *Cancer Cell* **4** 223–238. (doi:10.1016/S1535-6108(03)00197-1)
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. *BMJ* **330** 1304–1305. (doi:10.1136/bmj.38415.708634.F7)
- Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, Phillips TA, Metheny T, Aversman S, Yeh HW *et al.* 2013 Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10% weight loss in postmenopausal women. *Breast Cancer Research and Treatment* **142** 119–132. (doi:10.1007/s10549-013-2730-8)
- Fagan HB, Wender R, Myers RE & Petrelli N 2011 Obesity and cancer screening according to race and gender. *Journal of Obesity* **2011** 218250. (doi:10.1155/2011/218250)
- Fagherazzi G, Fabre A, Boutron-Ruault MC & Clavel-Chapelon F 2010 Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. *European Journal of Cancer Prevention* **19** 120–125. (doi:10.1097/CEJ.0b013e3283354918)
- Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD & Gaziano JM 2008 The association between statins and cancer incidence in a veterans population. *Journal of the National Cancer Institute* **100** 134–139. (doi:10.1093/jnci/djm286)
- Farwell WR, D'Avolio LW, Scranton RE, Lawler EV & Gaziano JM 2011 Statins and prostate cancer diagnosis and grade in a veterans population. *Journal of the National Cancer Institute* **103** 885–892. (doi:10.1093/jnci/djr108)
- Field AE, Camargo CA Jr & Ogino S 2013 The merits of subtyping obesity: one size does not fit all. *Journal of the American Medical Association* **310** 2147–2148. (doi:10.1001/jama.2013.281501)
- Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN *et al.* 2011 National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet* **377** 557–567. (doi:10.1016/S0140-6736(10)62037-5)
- Ford NA, Lashinger LM, Allott EH & Hursting SD 2013a Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link. *Frontiers in Oncology* **3** 209. (doi:10.3389/fonc.2013.00209)
- Ford NA, Nunez NP, Holcomb VB & Hursting SD 2013b IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression. *Endocrine-Related Cancer* **20** 39–51. (doi:10.1530/ERC-12-0329)
- Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F & Nicolucci A 2013 Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. *PLoS ONE* **8** e71583. (doi:10.1371/journal.pone.0071583)
- Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B & Aronson WJ 2004 Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. *Journal of Urology* **172** 520–524. (doi:10.1097/01.ju.0000135302.58378.ae)
- Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI & Partin AW 2005 Obesity and capsular incision at the time of open retropubic radical prostatectomy. *Journal of Urology* **174** 1798–1801. (doi:10.1097/01.ju.0000177077.53037.72)
- Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ & Terris MK 2006 Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. *Journal of Urology* **175** 500–504. (doi:10.1016/S0022-5347(05)00162-X)

- Friedman AM, Hemler JR, Rossetti E, Clemow LP & Ferrante JM 2012 Obese women's barriers to mammography and pap smear: the possible role of personality. *Obesity* **20** 1611–1617. (doi:10.1038/oby.2012.50)
- Fryar CD, Chen TC & Li X 2012 Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999–2010. *NCHS Data Brief* **1**–8.
- Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, hen J *et al.* 2014 Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. *Journal of the National Cancer Institute* **106** dju158. (doi:10.1093/jnci/dju158)
- Galet C, Gray A, Said JW, Castor B, Wan J, Beltran PJ, Calzone FJ, Elashoff D, Cohen P & Aronson WJ 2013 Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts. *International Journal of Molecular Sciences* **14** 13782–13795. (doi:10.3390/ijms140713782)
- Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A & Szabo E 2014 Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. *Cancer Prevention Research* **7** 867–885. (doi:10.1158/1940-6207.CAPR-13-0424)
- Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W & Bernstein JL 2011 Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. *Breast Cancer Research and Treatment* **130** 587–597. (doi:10.1007/s10549-011-1616-x)
- Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS & Maclean PS 2012 Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. *Cancer Research* **72** 6490–6501. (doi:10.1158/0008-5472.CAN-12-1653)
- Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG & Yee D 2010 Diabetes and cancer: a consensus report. *Diabetes Care* **33** 1674–1685. (doi:10.2337/dc10-0666)
- Goodwin PJ & Pritchard KI 2010 Obesity and hormone therapy in breast cancer: an unfinished puzzle. *Journal of Clinical Oncology* **28** 3405–3407. (doi:10.1200/JCO.2010.29.5113)
- Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK & Hood N 2012 Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. *Journal of Clinical Oncology* **30** 164–171. (doi:10.1200/JCO.2011.36.2723)
- Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, Blackburn GL, Findlay B, Gralow JR, ukherjee S *et al.* 2014 Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. *Journal of Clinical Oncology* **32** 2231–2239. (doi:10.1200/JCO.2013.53.1517)
- Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL *et al.* 2012 Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology* **30** 1553–1561. (doi:10.1200/JCO.2011.39.9436)
- Grubb RL III, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD *et al.* 2009 Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer screening trial. *Cancer Epidemiology, Biomarkers & Prevention* **18** 748–751. (doi:10.1158/1055-9965.EPI-08-0938)
- Gu Q P-RR, Burt VL & Kit BK 2014 Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. *NCHS Data Brief* **1**–8.
- Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P & Mukhtar H 2004 Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. *Cancer Research* **64** 3334–3343. (doi:10.1158/0008-5472.CAN-03-2422)
- Hakkak R, MacLeod S, Shaaf S, Holley AW, Simpson P, Fuchs G, Jo CH, Kieber-Emmons T & Korourian S 2007 Obesity increases the incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in an ovariectomized Zucker rat model. *International Journal of Oncology* **30** 557–563. (doi:10.3892/ijo.30.3.557)
- Hardie DG & Alessi DR 2013 LKB1 and AMPK and the cancer-metabolism link – ten years after. *BMC Biology* **11** 36. (doi:10.1186/1741-7007-11-36)
- Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR & Sellers TA 2005 Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. *Cancer Epidemiology, Biomarkers & Prevention* **14** 656–661. (doi:10.1158/1055-9965.EPI-04-0001)
- Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG *et al.* 2011 The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. *International Journal of Obesity* **35** 714–727. (doi:10.1038/ijo.2010.171)
- He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH & Yeung SC 2012 Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. *Annals of Oncology* **23** 1771–1780. (doi:10.1093/annonc/mdr534)
- Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, handrasekharan S *et al.* 2007 Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biology* **8** R76. (doi:10.1186/gb-2007-8-5-r76)
- Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM *et al.* 2002 Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. *Cancer Research* **62** 5405–5407.
- Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L & Canadian Cancer Registries Epidemiology Research Group 2012 Dietary cholesterol intake and cancer. *Annals of Oncology* **23** 491–500. (doi:10.1093/annonc/mdr155)
- Hu MB, Liu SH, Jiang HW, Bai PD & Ding Q 2014 Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. *PLoS ONE* **9** e106677. (doi:10.1371/journal.pone.0106677)
- Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, Vogel VG & Weissfeld JL 2008 Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. *Cancer Epidemiology, Biomarkers & Prevention* **17** 680–687. (doi:10.1158/1055-9965.EPI-07-2739)
- Hursting SD, Smith SM, Lashinger LM, Harvey AE & Perkins SN 2010 Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. *Carcinogenesis* **31** 83–89. (doi:10.1093/carcin/bgp280)
- Ioannides SJ, Barlow PL, Elwood JM & Porter D 2014 Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. *Breast Cancer Research and Treatment* **147** 237–248. (doi:10.1007/s10549-014-3091-7)
- Irwin ML 2014 Weight loss interventions and breast cancer survival: the time is now. *Journal of Clinical Oncology* **32** 2197–2199. (doi:10.1200/JCO.2014.56.4583)
- Jacobs EJ, Stevens VL, Newton CC & Gapstur SM 2012 Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Causes & Control* **23** 1289–1296. (doi:10.1007/s10552-012-0006-y)
- Jakovljevic J, Touillaud MS, Bondy ML, Singletary SE, Pillow PC & Chang S 2002 Dietary intake of selected fatty acids, cholesterol and carotenoids and estrogen receptor status in premenopausal breast cancer patients. *Breast Cancer Research and Treatment* **75** 5–14. (doi:10.1023/A:1016588629495)

- Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. *CA: A Cancer Journal for Clinicians* **61** 69–90. (doi:10.3322/caac.20107)
- Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN & Giordano SH 2013 Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. *Annals of Oncology* **24** 2506–2514. (doi:10.1093/annonc/mdt224)
- Joshua CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC & Platz EA 2011 Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. *Cancer Prevention Research* **4** 544–551. (doi:10.1158/1940-6207.CAPR-10-0257)
- Kasper JS & Giovannucci E 2006 A meta-analysis of diabetes mellitus and the risk of prostate cancer. *Cancer Epidemiology, Biomarkers & Prevention* **15** 2056–2062. (doi:10.1158/1055-9965.EPI-06-0410)
- Kasper JS, Liu Y & Giovannucci E 2009 Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. *International Journal of Cancer* **124** 1398–1403. (doi:10.1002/ijc.24044)
- Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE & Bergstralh EJ 2013 Effect of metformin on prostate cancer outcomes after radical prostatectomy. *Urologic Oncology* **32** 43e1–43e7. (doi:10.1016/j.urolonc.2013.05.005)
- Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R & Buist DS 2008 Obesity, mammography use and accuracy, and advanced breast cancer risk. *Journal of the National Cancer Institute* **100** 1724–1733. (doi:10.1093/jnci/djn388)
- Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL & Freedland SJ 2011 Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. *BJU International* **110** 492–498. (doi:10.1111/j.1464-410X.2011.10754.x)
- Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE *et al.* 2007 COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. *Lancet Oncology* **8** 912–920. (doi:10.1016/S1470-2045(07)70280-2)
- Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH & Samet JM 2011 Total cholesterol and cancer risk in a large prospective study in Korea. *Journal of Clinical Oncology* **29** 1592–1598. (doi:10.1200/JCO.2010.31.5200)
- Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, ohen P *et al.* 2008 Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. *Cancer Research* **68** 3066–3073. (doi:10.1158/0008-5472.CAN-07-5616)
- Kowall B, Stang A, Rathmann W & Kostev K 2015 No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. *Pharmacoepidemiology and Drug Safety* **24** 865–874. (doi:10.1002/pds.3823)
- Krycer JR & Brown AJ 2013 Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. *Biochimica et Biophysica Acta* **1835** 219–229. (doi:10.1016/j.bbcan.2013.01.002)
- Kumar AS, Benz CC, Shim V, Minami CA, Moore DH & Esserman LJ 2008 Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. *Cancer Epidemiology, Biomarkers & Prevention* **17** 1028–1033. (doi:10.1158/1055-9965.EPI-07-0726)
- Kuoppala J, Lamminpää A & Pukkala E 2008 Statins and cancer: a systematic review and meta-analysis. *European Journal of Cancer* **44** 2122–2132. (doi:10.1016/j.ejca.2008.06.025)
- Kwan ML, Habel LA, Flick ED, Quesenberry CP & Caan B 2008 Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. *Breast Cancer Research and Treatment* **109** 573–579. (doi:10.1007/s10549-007-9683-8)
- Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. *International Journal of Cancer* **121** 856–862. (doi:10.1002/ijc.22717)
- Lashinger LM, Ford NA & Hursting SD 2014a Interacting inflammatory and growth factor signals underlie the obesity-cancer link. *Journal of Nutrition* **144** 109–113. (doi:10.3945/jn.113.178533)
- Lashinger LM, Rossi EL & Hursting SD 2014b Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation. *Clinical Pharmacology and Therapeutics* **96** 458–463. (doi:10.1038/clpt.2014.136)
- Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, Falzarano SM, Magi-Galluzzi C, Klein EA & Ting AH 2013 Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. *Cancer Research* **73** 1211–1218. (doi:10.1158/0008-5472.CAN-12-3128)
- Lega IC, Shah PS, Margel D, Beyene J, Rochon PA & Lipscombe LL 2014 The effect of metformin on mortality following cancer among patients with diabetes. *Cancer Epidemiology, Biomarkers & Prevention* **23** 1974–1984. (doi:10.1158/1055-9965.EPI-14-0327)
- Li C, Ford ES, McGuire LC & Mokdad AH 2007 Increasing trends in waist circumference and abdominal obesity among US adults. *Obesity* **15** 216–224. (doi:10.1038/oby.2007.505)
- Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN & Brewster AM 2008 Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. *Journal of Clinical Oncology* **26** 4072–4077. (doi:10.1200/JCO.2007.14.4527)
- Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF & Hla T 2001 Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. *Journal of Biological Chemistry* **276** 18563–18569. (doi:10.1074/jbc.M010787200)
- Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, Gao Y, Qin X & Li S 2014 Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. *BMC Medicine* **12** 55. (doi:10.1186/1741-7015-12-55)
- Liu J, Ramakrishnan SK, Khuder SS, Kaw MK, Muturi HT, Lester SG, Lee SJ, Fedorova LV, Kim AJ, Mohamed IE *et al.* 2015 High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene. *Molecular Metabolism* **4** 186–198. (doi:10.1016/j.molmet.2014.12.011)
- Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP & Frank PG 2010 A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. *American Journal of Pathology* **177** 3180–3191. (doi:10.2353/ajpath.2010.100568)
- Lyman GH & Sparreboom A 2013 Chemotherapy dosing in overweight and obese patients with cancer. *Nature Reviews. Clinical Oncology* **10** 451–459. (doi:10.1038/nrclinonc.2013.108)
- Lyman GH, Dale DC & Crawford J 2003 Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. *Journal of Clinical Oncology* **21** 4524–4531. (doi:10.1200/JCO.2003.05.002)
- Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC & Schedin P 2011 Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. *Nature Medicine* **17** 1109–1115. (doi:10.1038/nm.2416)
- Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M & Stampfer MJ 2008 Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. *Lancet Oncology* **9** 1039–1047. (doi:10.1016/S1470-2045(08)70235-3)
- MacInnis RJ & English DR 2006 Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. *Cancer Causes & Control* **17** 989–1003. (doi:10.1007/s10552-006-0049-z)
- Makari-Judson G, Braun B, Jerry DJ & Mertens WC 2014 Weight gain following breast cancer diagnosis: Implication and proposed

- mechanisms. *World Journal of Clinical Oncology* **5** 272–282. (doi:10.5306/wjco.v5.i3.272)
- Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC & Fleshner N 2013 Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. *Journal of Clinical Oncology* **31** 3069–3075. (doi:10.1200/JCO.2012.46.7043)
- Martin RM, Vatten L, Gunnell D, Romundstad P & Nilsen TI 2009 Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. *Cancer Causes & Control* **20** 1181–1192. (doi:10.1007/s10552-009-9319-x)
- Maruthur NM, Bolen S, Brancati FL & Clark JM 2009 Obesity and mammography: a systematic review and meta-analysis. *Journal of General Internal Medicine* **24** 665–677. (doi:10.1007/s11606-009-0939-3)
- Mass AY, Agalliu I, Laze J & Lepor H 2012 Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. *Journal of Urology* **188** 786–791. (doi:10.1016/j.juro.2012.05.011)
- Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA & Adamovich E 2007 Obesity is not predictive of overall survival following permanent prostate brachytherapy. *American Journal of Clinical Oncology* **30** 588–596. (doi:10.1097/COC.0b013e318068b506)
- Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE & Nurses' Health S 2003 Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. *Diabetes Care* **26** 1752–1758. (doi:10.2337/diacare.26.6.1752)
- Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT *et al.* 2008 Epidemiology of basal-like breast cancer. *Breast Cancer Research and Treatment* **109** 123–139. (doi:10.1007/s10549-007-9632-6)
- Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP & Grossmann ME 2013 Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. *Cancer Prevention Research* **6** 540–547. (doi:10.1158/1940-6207.CAPR-13-0033)
- Moller E, Adami HO, Mucci LA, Lundholm C, Belloc R, Johansson JE, Gronberg H & Balter K 2013 Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. *Cancer Causes & Control* **24** 2143–2155. (doi:10.1007/s10552-013-0291-0)
- Mondul AM, Clipp SL, Helzlsouer KJ & Platz EA 2010 Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. *Cancer Causes & Control* **21** 61–68. (doi:10.1007/s10552-009-9434-8)
- Mondul AM, Weinstein SJ, Virtamo J & Albanes D 2011 Serum total and HDL cholesterol and risk of prostate cancer. *Cancer Causes & Control* **22** 1545–1552. (doi:10.1007/s10552-011-9831-7)
- Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ *et al.* 2014 Influence of age on incident diabetes and cardiovascular disease among prostate cancer survivors receiving androgen deprivation therapy. *Journal of Urology* **193** 1226–1231. (doi:10.1016/j.juro.2014.11.006)
- Mostaghel EA, Solomon KR, Pelton K, Freeman MR & Montgomery RB 2012 Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. *PLoS ONE* **7** e30062. (doi:10.1371/journal.pone.0030062)
- Moyer VA & U.S. Preventative Services Task Force 2012 Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* **157** 120–134. (doi:10.7326/0003-4819-157-2-201207170-00459)
- Munsell MF, Sprague BL, Berry DA, Chisholm G & Trentham-Dietz A 2014 Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. *Epidemiologic Reviews* **36** 114–136. (doi:10.1093/epirev/mxt010)
- Murtola TJ, Tammela TL, Lahtela J & Auvinen A 2008 Antidiabetic medication and prostate cancer risk: a population-based case-control study. *American Journal of Epidemiology* **168** 925–931. (doi:10.1093/aje/kwn190)
- Murtola TJ, Visvanathan K, Artama M, Vainio H & Pukkala E 2014 Statin use and breast cancer survival: a nationwide cohort study from Finland. *PLoS ONE* **9** e110231. (doi:10.1371/journal.pone.0110231)
- Narayanan BA, Narayanan NK, Pittman B & Reddy BS 2004 Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. *Clinical Cancer Research* **10** 7727–7737. (doi:10.1158/1078-0432.CCR-04-0732)
- Narayanan BA, Narayanan NK, Pittman B & Reddy BS 2006 Adenocarcinoma of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. *Prostate* **66** 257–265. (doi:10.1002/pros.20331)
- Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM *et al.* 2013 Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. *Obesity* **21** E439–E447. (doi:10.1002/oby.20135)
- Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V *et al.* 2013 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. *Science* **342** 1094–1098. (doi:10.1126/science.1241908)
- Nielsen SF, Nordestgaard BG & Bojesen SE 2012 Statin use and reduced cancer-related mortality. *New England Journal of Medicine* **367** 1792–1802. (doi:10.1056/NEJMoa1201735)
- Niraula S, Ocana A, Ennis M & Goodwin PJ 2012 Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. *Breast Cancer Research and Treatment* **134** 769–781. (doi:10.1007/s10549-012-2073-x)
- Nogueira LM, Dunlap SM, Ford NA & Hursting SD 2012 Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. *Endocrine-Related Cancer* **19** 57–68. (doi:10.1530/ERC-11-0213)
- Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC & Hursting SD 2008 Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. *Nutrition and Cancer* **60** 534–541. (doi:10.1080/01635580801966195)
- Ogden CL, Carroll MD, Kit BK & Flegal KM 2014 Prevalence of childhood and adult obesity in the United States, 2011–2012. *Journal of the American Medical Association* **311** 806–814. (doi:10.1001/jama.2014.732)
- Pape-Ansorge KA, Grande JP, Christensen TA, Maihle NJ & Cleary MP 2002 Effect of moderate caloric restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-Neu female mice. *Nutrition and Cancer* **44** 162–168. (doi:10.1207/S15327914NC4402_07)
- Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogumbo R & Mucci LA 2013 Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. *Annals of Oncology* **24** 1427–1434. (doi:10.1093/annonc/mdt077)
- Patel T, Hruby G, Badani K, Abate-Shen C & McKiernan JM 2010 Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. *Urology* **76** 1240–1244. (doi:10.1016/j.urology.2010.03.059)
- de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, Gomez-Acebo I, Pollan M & Llorca J 2015 Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. *Breast Cancer Research and Treatment* **149** 525–536. (doi:10.1007/s10549-015-3267-9)
- Pelton K, Freeman MR & Solomon KR 2012 Cholesterol and prostate cancer. *Current Opinion in Pharmacology* **12** 751–759. (doi:10.1016/j.coph.2012.07.006)
- Phipps AI, Malone KE, Porter PL, Daling JR & Li CI 2008 Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. *Cancer Epidemiology, Biomarkers & Prevention* **17** 2078–2086. (doi:10.1158/1055-9965.EPI-08-0206)
- Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, Tjonneland A, Severinsen MT, Overvad K, ohrmann S *et al.* 2008 Body size and risk of prostate cancer in the European prospective investigation into cancer

- and nutrition. *Cancer Epidemiology, Biomarkers & Prevention* **17** 3252–3261. (doi:10.1158/1055-9965.EPI-08-0609)
- Platz EA, Clinton SK & Giovannucci E 2008 Association between plasma cholesterol and prostate cancer in the PSA era. *International Journal of Cancer* **123** 1693–1698. (doi:10.1002/ijc.23715)
- Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhauser ML, Klein EA, Thompson IM Jr & Kristal AR 2009 Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. *Cancer Epidemiology, Biomarkers & Prevention* **18** 2807–2813. (doi:10.1158/1055-9965.EPI-09-0472)
- Pou KM, Massaro JM, Hoffmann U, Lieb K, Vasan RS, O'Donnell CJ & Fox CS 2009 Patterns of abdominal fat distribution: the Framingham Heart Study. *Diabetes Care* **32** 481–485. (doi:10.2337/dc08-1359)
- Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO & Sorensen HT 2014 Metformin use and prostate cancer risk. *European Urology* **66** 1012–1020. (doi:10.1016/j.eururo.2014.04.027)
- Renahan AG 2009 Bariatric surgery, weight reduction, and cancer prevention. *Lancet Oncology* **10** 640–641. (doi:10.1016/S1470-2045(09)70170-6)
- Renahan AG, Tyson M, Egger M, Heller RF & Zwahlen M 2008 Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* **371** 569–578. (doi:10.1016/S0140-6736(08)60269-X)
- Ridker PM & Cook NR 2013 Statins: new American guidelines for prevention of cardiovascular disease. *Lancet* **382** 1762–1765. (doi:10.1016/S0140-6736(13)62388-0)
- Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H & Isola J 2002 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. *Cancer Research* **62** 632–635.
- Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A & Thun MJ 2001 Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. *Cancer Epidemiology, Biomarkers & Prevention* **10** 345–353.
- Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ & Calle EE 2007 Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiology, Biomarkers & Prevention* **16** 63–69. (doi:10.1158/1055-9965.EPI-06-0754)
- Rodvold KA, Rushing DA & Tewksbury DA 1988 Doxorubicin clearance in the obese. *Journal of Clinical Oncology* **6** 1321–1327.
- Rogozina OP, Nkhata KJ, Nagle EJ, Grande JP & Cleary MP 2013 The protective effect of intermittent calorie restriction on mammary tumorigenesis is not compromised by consumption of a high fat diet during refeeding. *Breast Cancer Research and Treatment* **138** 395–406. (doi:10.1007/s10549-013-2464-7)
- Rosenberg LU, Einarsson K, Friman EI, Wedren S, Dickman PW, Hall P & Magnusson C 2006 Risk factors for hormone receptor-defined breast cancer in postmenopausal women. *Cancer Epidemiology, Biomarkers & Prevention* **15** 2482–2488. (doi:10.1158/1055-9965.EPI-06-0489)
- Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D & Force USPST 2007 Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. *Annals of Internal Medicine* **146** 376–389. (doi:10.7326/0003-4819-146-5-200703060-00010)
- Roy M, Kung HJ & Ghosh PM 2011 Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. *American Journal of Cancer Research* **1** 542–561.
- Rundle AG & Neugut AI 2009 Modeling the effects of obesity and weight gain on PSA velocity. *Prostate* **69** 1573–1578. (doi:10.1002/pros.21005)
- Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P & Moul JW 2007 Relationship between body mass index and prostate cancer screening in the United States. *Journal of Urology* **177** 493–498. (doi:10.1016/j.juro.2006.09.059)
- Schmitz KH, Neuhauser ML, Agurs-Collins T, Zanetti KA, Cadmus-Bertram L, Dean LT & Drake BF 2013 Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. *Journal of the National Cancer Institute* **105** 1344–1354. (doi:10.1093/jnci/djt223)
- Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H & Messing E 2013 Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. *BJU International* **111** E71–E77. (doi:10.1111/j.1464-410X.2012.11527.x)
- Shafique K, McLoone P, Qureshi K, Leung H, Hart C & Morrison DS 2012 Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up. *BMC Cancer* **12** 25. (doi:10.1186/1471-2407-12-25)
- Siegel RL, Miller KD & Jemal A 2015 Cancer statistics, 2015. *CA: A Cancer Journal for Clinicians* **65** 5–29. (doi:10.3322/caac.21254)
- Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B *et al.* 2007 Effects of bariatric surgery on mortality in Swedish obese subjects. *New England Journal of Medicine* **357** 741–752. (doi:10.1056/NEJMoa066254)
- Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Ahlgren S *et al.* 2009 Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. *Lancet Oncology* **10** 653–662. (doi:10.1016/S1470-2045(09)70159-7)
- Smith MR 2007 Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. *Clinical Cancer Research* **13** 241–245. (doi:10.1158/1078-0432.CCR-06-2086)
- Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr *et al.* 2012 Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. *Cancer* **118** 5937–5946. (doi:10.1002/cncr.27527)
- Srokowski TP, Fang S, Hortobagyi GN & Giordano SH 2009 Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. *Journal of Clinical Oncology* **27** 2170–2176. (doi:10.1200/JCO.2008.17.5935)
- Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, Bahalim AN, McIntire RK, Gutierrez HR, Owan M *et al.* 2012 National, regional, and global trends in adult overweight and obesity prevalences. *Population Health Metrics* **10** 22. (doi:10.1186/1478-7954-10-22)
- Subbaramaiah K, Norton L, Gerald W & Dannenberg AJ 2002 Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. *Journal of Biological Chemistry* **277** 18649–18657. (doi:10.1074/jbc.M111415200)
- Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA & Dannenberg AJ 2012 Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. *Cancer Discovery* **2** 356–365. (doi:10.1158/2159-8290.CD-11-0241)
- Suissa S & Azoulay L 2012 Metformin and the Risk of Cancer: Time-related biases in observational studies. *Diabetes Care* **35** 2665–2673. (doi:10.2337/dc12-0788)
- Sundaram S, Freermerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA *et al.* 2013 Role of HGF in obesity-associated tumorigenesis: C3(1)-Tag mice as a model for human basal-like breast cancer. *Breast Cancer Research and Treatment* **142** 489–503. (doi:10.1007/s10549-013-2741-5)
- Sundaram S, Le TL, Essaid L, Freermerman AJ, Huang MJ, Galanko JA, McNaughton KK, Bendt KM, Darr DB, Troester MA *et al.* 2014a Weight loss reversed obesity-induced HGF/c-Met pathway and basal-like breast cancer progression. *Frontiers in Oncology* **4** 175. (doi:10.3389/fonc.2014.00175)

- Sundaram S, Freerman AJ, Galanko JA, McNaughton KK, Bendt KM, Darr DB, Troester MA & Makowski L 2014b Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice. *PLoS ONE* **9** e111394. (doi:10.1371/journal.pone.0111394)
- Suzuki R, Orsini N, Saji S, Key TJ & Wolk A 2009 Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status – a meta-analysis. *International Journal of Cancer* **124** 698–712. (doi:10.1002/ijc.23943)
- Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ & Ma CX 2014 Body mass index, diabetes, and triple-negative breast cancer prognosis. *Breast Cancer Research and Treatment* **146** 189–197. (doi:10.1007/s10549-014-3002-y)
- Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ & Neugut AI 2004 Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. *Journal of the American Medical Association* **291** 2433–2440. (doi:10.1001/jama.291.20.2433)
- Thomas JA II, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M & Freedland SJ 2010 Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. *Prostate Cancer and Prostatic Diseases* **13** 350–355. (doi:10.1038/pcan.2010.24)
- Thompson HJ & McTiernan A 2011 Weight cycling and cancer: weighing the evidence of intermittent caloric restriction and cancer risk. *Cancer Prevention Research* **4** 1736–1742. (doi:10.1158/1940-6207.CAPR-11-0133)
- Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, Stijleman IJ, Green JE, Bennett C, Juliana MM *et al.* 2015 Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. *Cancer Prevention Research* **8** 231–239. (doi:10.1158/1940-6207.CAPR-14-0181-T)
- Togawa K, Ma H, Sullivan-Halley J, Neuhauser ML, Imayama I, Baumgartner KB, Smith AW, Alfano CM, McTiernan A, allard-Barbash R *et al.* 2014 Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. *Breast Cancer Research* **16** 414. (doi:10.1186/s13058-014-0414-x)
- Tsai H, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Yood MU, Smith MR & Potosky AL 2014 Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. *Journal of Urology* **193** 1956–1962. (doi:10.1016/j.juro.2014.12.027)
- Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, zoulaki I *et al.* 2014 Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. *Diabetes Care* **37** 2522–2532. (doi:10.2337/dc14-0584)
- Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE & Ioannidis JP 2015a Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. *BMJ* **350** g7607. (doi:10.1136/bmj.g7607)
- Tsilidis KK, Allen NE, Appleby PN, Rohrmann S, Nothlings U, Arriola L, Gunter MJ, Chajes V, Rinaldi S, omieu I *et al.* 2015b Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. *International Journal of Cancer* **136** 372–381. (doi:10.1002/ijc.28989)
- Undela K, Srikanth V & Bansal D 2012 Statin use and risk of breast cancer: a meta-analysis of observational studies. *Breast Cancer Research and Treatment* **135** 261–269. (doi:10.1007/s10549-012-2154-x)
- Vazquez-Martin A, Oliveras-Ferraro C & Menendez JA 2009 The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. *Cell Cycle* **8** 88–96. (doi:10.4161/cc.8.1.7499)
- Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Adriole GL & Freedland SJ 2014 Aspirin, NSAID and risk of prostate cancer: results from the REDUCE study. *Clinical Cancer Research* **15** 756–762. (doi:10.1158/1078-0432)
- Vrieling A, Buck K, Kaaks R & Chang-Claude J 2010 Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. *Breast Cancer Research and Treatment* **123** 641–649. (doi:10.1007/s10549-010-1116-4)
- Wang D & Dubois RN 2010 Eicosanoids and cancer. *Nature Reviews. Cancer* **10** 181–193. (doi:10.1038/nrc2809)
- Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS *et al.* 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* **4** 209–221. (doi:10.1016/S1535-6108(03)00215-0)
- Wang X, Lin YW, Wu J, Zhu Y, Xu XL, Xu X, Liang Z, Hu ZH, Li SQ, Zheng XY *et al.* 2014 Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. *World Journal of Surgical Oncology* **12** 304. (doi:10.1186/1477-7819-12-304)
- Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL & Freedland SJ 2011 Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. *Prostate Cancer and Prostatic Diseases* **14** 361–366. (doi:10.1038/pcan.2011.42)
- Woditschka S, Haag JD, Mau B, Lubet RA & Gould MN 2008 Chemo-preventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. *Breast Cancer Research* **10** R18. (doi:10.1186/bcr1864)
- Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R & Wockel A 2012 Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. *Breast Cancer Research and Treatment* **131** 925–931. (doi:10.1007/s10549-011-1874-7)
- World Cancer Research Fund/American Institute for Cancer Research 2007 *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective*. Washington DC: AICR.
- Wright JL & Stanford JL 2009 Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. *Cancer Causes & Control* **20** 1617–1622. (doi:10.1007/s10552-009-9407-y)
- Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A & Leitzmann MF 2007 Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. *Cancer* **109** 675–684. (doi:10.1002/cncr.22443)
- Wu C, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL & Freedland SJ 2013 Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. *BJU International* **111** E310–E318. (doi:10.1111/j.1464-410X.2012.11687.x)
- Xu H, Hu MB, Bai PD, Zhu WH, Ding Q & Jiang HW 2014 Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression? *International Urology and Nephrology* **46** 2327–2334. (doi:10.1007/s11255-014-0823-x)
- Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, ox A *et al.* 2011 Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *Journal of the National Cancer Institute* **103** 250–263. (doi:10.1093/jnci/djq526)
- Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T & Wada S 2000 Expression of cyclooxygenase-2 in prostate carcinoma. *Cancer* **89** 589–596. (doi:10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C)
- Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H, Gao X & He X 2014a Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. *PLoS ONE* **9** e116327. (doi:10.1371/journal.pone.0116327)
- Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S & Azoulay L 2014b Use of statins and the risk of death in patients with prostate cancer. *Journal of Clinical Oncology* **32** 5–11. (doi:10.1200/JCO.2013.49.4757)

- Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, Qiu J & Lei H 2012 Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. *Acta Diabetologica* **49** S235–S246. (doi:10.1007/s00592-012-0439-5)
- Zhang P, Li H, Tan X, Chen L & Wang S 2013 Association of metformin use with cancer incidence and mortality: a meta-analysis. *Cancer Epidemiology* **37** 207–218. (doi:10.1016/j.canep.2012.12.009)
- Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J, Liu C & Guo H 2015 Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. *Oncology Letters* **9** 1307–1312. (doi:10.3892/ol.2014.2841)
- Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1996 Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE₂ via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. *Endocrinology* **137** 5739–5742. (doi:10.1210/endo.137.12.8940410)
- Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N *et al.* 2001 Role of AMP-activated protein kinase in mechanism of metformin action. *Journal of Clinical Investigation* **108** 1167–1174. (doi:10.1172/JCI13505)
- Zhuang L, Lin J, Lu ML, Solomon KR & Freeman MR 2002 Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. *Cancer Research* **62** 2227–2231.

Received in final form 24 August 2015

Accepted 15 September 2015

Made available online as an Accepted Preprint

15 September 2015